Glioma Market Overview
Glioma is the most common central nervous system (CNS) neoplasm originating from glial cells. These tumors are highly infiltrative and affect surrounding brain tissue, often leading to neurological dysfunction and poor prognosis, particularly in high-grade gliomas such as glioblastoma.
Glioma Epidemiology Segmentation
<ul>
<li dir="ltr" aria-level="1">
Total Incident Cases of Glioma
</li>
<li dir="ltr" aria-level="1">
Grade-specific Incident Cases of Glioma
</li>
<li dir="ltr" aria-level="1">
Age-specific Incident Cases of Glioma
</li>
<li dir="ltr" aria-level="1">
Type-specific Incident Cases of Glioma
</li>
</ul>
Glioma Epidemiology
<ul>
<li dir="ltr" aria-level="1">
Across the 7 Major Markets (7MM), the total incident population of glioma was estimated at approximately 51K cases in 2025.
</li>
<li dir="ltr" aria-level="1">
In the United States, grade-specific analysis showed that approximately 80% of glioma cases were high-grade, while 20% were low-grade.
</li>
<li dir="ltr" aria-level="1">
Among gliomas affecting other parts of the central nervous system in the United States, glioblastoma was significantly more prevalent in adults than in pediatric populations, followed by anaplastic astrocytoma, which also showed higher prevalence in adults.
</li>
</ul>
Glioma Market
<ul>
<li dir="ltr" aria-level="1">
Within the 7 Major Markets (7MM), the glioma market is expected to expand significantly during the forecast period (2026&ndash;2036), driven by advancements in treatment approaches, increasing research activity, and emerging targeted therapies.
</li>
<li dir="ltr" aria-level="1">
The glioma market size across the 7MM was estimated at approximately USD 1 billion in 2025.
</li>
<li dir="ltr" aria-level="1">
The United States accounted for nearly 65% of the total market share in 2025.
</li>
<li dir="ltr" aria-level="1">
In Japan, OPTUNE &plusmn; TMZ captured the highest market share in 2025 and is expected to continue generating substantial revenue during the forecast period.
</li>
<li dir="ltr" aria-level="1">
The growing focus on precision medicine, tumor-targeted therapies, immunotherapy, and innovative drug delivery approaches is expected to reshape the glioma treatment landscape over the coming decade.
</li>
</ul>
Glioma Market Drivers
<ul>
<li dir="ltr" aria-level="1">
Increasing prevalence of glioma and rising awareness regarding brain tumor diagnosis are contributing to expanding treatment demand globally.
</li>
<li dir="ltr" aria-level="1">
Advancements in treatment strategies, including tumor-treating fields, targeted therapies, immunotherapies, and vaccine-based approaches, are driving innovation in glioma management.
</li>
<li dir="ltr" aria-level="1">
Growing investment in clinical research and the emergence of novel therapeutic combinations are accelerating the development of next-generation glioma therapies.
</li>
</ul>
Glioma Market Barriers
<ul>
<li dir="ltr" aria-level="1">
Current standard-of-care treatments remain largely non-curative, with recurrence rates approaching 90&ndash;95% in high-grade gliomas such as glioblastoma.
</li>
<li dir="ltr" aria-level="1">
The lack of reliable biomarkers for diagnosis, recurrence monitoring, and therapy response continues to limit effective patient stratification and treatment optimization.
</li>
<li dir="ltr" aria-level="1">
Despite promising preclinical findings, many targeted therapies and investigational agents have failed in late-stage clinical trials, highlighting the complexity of glioma biology and treatment resistance.
</li>
</ul>
Emerging Glioma Drugs
<ul>
<li dir="ltr" aria-level="1">
DCVax-L
</li>
<li dir="ltr" aria-level="1">
Enzastaurin
</li>
<li dir="ltr" aria-level="1">
Paxalisib (GDC-0084)
</li>
<li dir="ltr" aria-level="1">
And others
</li>
</ul>
Key Glioma Companies
<ul>
<li dir="ltr" aria-level="1">
Northwest Therapeutics
</li>
<li dir="ltr" aria-level="1">
Denovo Pharma
</li>
<li dir="ltr" aria-level="1">
Kazia Therapeutics
</li>
<li dir="ltr" aria-level="1">
Merck
</li>
<li dir="ltr" aria-level="1">
Daiichi Sankyo
</li>
<li dir="ltr" aria-level="1">
Novartis
</li>
<li dir="ltr" aria-level="1">
Pfizer
</li>
<li dir="ltr" aria-level="1">
Amgen
</li>
<li dir="ltr" aria-level="1">
And others
</li>
</ul>
&nbsp;

Glioma Market (US)

Glioma Market Infographic (US)

Glioma Infographic provides deatiled analysis of the Symptoms, Treatment, epidemiology, companies, drugs, developments in a short guide to understand the problem and market landscape in the US market.